Board of Directors

Lynn Durham

Chairman of the board

Lynn is a biotech entrepreneur and the founder of STALICLA SA. Her lifelong involvement with the Autism community has brought her to develop a unique patient centric vision of Drug Development to address the unmet medical needs of patients with Autism Spectrum Disorder. Fostering on a strong network within the neuroscience, clinical research and data science communities, she launched STALICLA in May 2017 and is leading its early fast-paced growth. Lynn has extensive experience in Business development and has worked in the past for the World Economic forum, venture capital and start-up promoting initiatives. Lynn holds a double degree in economic history and political sciences and a Master’s degree from Rouen Business School. She is also currently finalizing a post graduate degree in clinical trials and drug development at the Faculty of medicine of the University of Geneva.

Benjamin Dubois


Benjamin is the Global Head of Overlay Management at Edmond de Rothschild Asset Management Suisse and a member of the enlarged executive committee of EDRAM. He holds a Post-Graduate Master’s Degree in Engineering, IT and Mathematics and a Masters in Finance from ESSEC business school.

Hugo Ferreira


Hugo Ferreira is Director of Huniel Conseil S.A.(created in 2014) in Geneva. He joined in 1991 La Compagnie Benjamin de Rothschild Deputy General Manager until end of 2013. He has an extensive experience in finance (finance director, treasurer, structuring loan department, corporate finance), working for well-known institutions such as Nestlé (Switzerland and the USA), Citicorp Investment Bank (New York), as well as the Group Tradition. He is a non-executive director of Cobepa and several Private Equity funds.

Hugo is a commercial engineer from the Solvay School (Université Libre de Bruxelles) and holds a MBA from Columbia University (New York).

Jacques Bonvin


Jacques Bonvin is Partner at Tavernier Tschartz. After training mainly in international commercial arbitration and litigation, Jacques Bonvin has specialized over the last twenty years, and is now active in corporate law, international mergers and acquisitions and corporate finance, including private equity and venture capital, with a special emphasis on the technology and biotechnology sector. Jacques Bonvin regularly advises board of directors on corporate governance and strategic issues.

Search for content on Stalicla...